Treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu ) yielded clinically meaningful improvements in key outcome measures for patien...
Results of the phase 2 NeoAvAx trial (NCT03341845) presented during the 2022 Genitourinary Cancers Symposium indicated that the neoadjuvant combi...
Pembrolizumab ( Keytruda ) neoadjuvant therapy compared with placebo improved disease-free survival (DFS) in patients with renal cell carcinoma...
The Food and Drug Administration (FDA) has expanded the approval of Solosec® (secnidazole) to include treatment of female patients 12 years of ag...
Treatment with apalutamide (Erleada) resulted in a more significant early reduction in prostate-specific antigen (PSA) from baseline of 90% or mo...
Patient with metastatic castration-sensitive prostate cancer (CSPC) treated with androgen deprivation therapy (ADT) and docetaxel experienced bet...
More than a decade after its founding, Agios Pharmaceuticals has its first FDA green light. With the approval for Pyrukynd to treat hemolytic ane...
While the survival rate for children with acute lymphoblastic leukemia (ALL)—the most common cancer in children—is more than 80%, survival among ...
Treatment with aspirin did not result in an invasive disease-free survival (iDFS) benefit for patients with stage II or III HER2-negative breast ...
The FDA has granted fast track designation to pidnarulex (CX-5461) for the treatment of ovarian and breast cancer with BRCA1/2, PALB2, or other h...